Active Biotech AB Interim Report January - June 2011

August 11, 2011 08:30 (CEST)

· Laquinimod - results of Phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment 

· TASQ - recruitment of patients for the Phase III trial ongoing

· TASQ - partnership agreement initiated with Ipsen

· ANYARA - Phase III trial continues according to plan

· 57-57 - preparation for the start of the SSC exploratory clinical trial in progress

· ISI - project is proceeding as planned

· RhuDex(TM) - preparations for continued clinical development in progress

· Net sales SEK 228.8 M (6.1)

· Operating profit SEK 70.6 M  (loss: 102,4) 

· Profit after tax SEK 77.7 M (loss: 108.3)

· Earnings per share for the period amounted to SEK 1.14 (loss: 1.67)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
   
Hans Kolam     
CFO       
Tel: +46 (0)46-19 20 44    


Active Biotech AB
(Corp. Reg. No: 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00 

This report is also available at www.activebiotech.com  

Active Biotech AB Interim Report January – June 2011